DK0686045T3 - Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof - Google Patents

Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof

Info

Publication number
DK0686045T3
DK0686045T3 DK94909647T DK94909647T DK0686045T3 DK 0686045 T3 DK0686045 T3 DK 0686045T3 DK 94909647 T DK94909647 T DK 94909647T DK 94909647 T DK94909647 T DK 94909647T DK 0686045 T3 DK0686045 T3 DK 0686045T3
Authority
DK
Denmark
Prior art keywords
pct
stabilization
adjuvant
organic solvent
polypeptides
Prior art date
Application number
DK94909647T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey L Cleland
Andrew J S Jones
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0686045T3 publication Critical patent/DK0686045T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94909647T 1993-02-23 1994-02-17 Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof DK0686045T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2142193A 1993-02-23 1993-02-23
PCT/US1994/001666 WO1994019020A1 (en) 1993-02-23 1994-02-17 Excipient stabilization of polypeptides treated with organic solvents

Publications (1)

Publication Number Publication Date
DK0686045T3 true DK0686045T3 (da) 2001-03-05

Family

ID=21804127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909647T DK0686045T3 (da) 1993-02-23 1994-02-17 Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof

Country Status (17)

Country Link
US (3) US5589167A (cs)
EP (1) EP0686045B1 (cs)
JP (1) JP3698721B2 (cs)
CN (1) CN1108823C (cs)
AT (1) ATE197550T1 (cs)
AU (1) AU685784B2 (cs)
CZ (1) CZ296649B6 (cs)
DE (1) DE69426292T2 (cs)
DK (1) DK0686045T3 (cs)
ES (1) ES2153418T3 (cs)
GR (1) GR3035383T3 (cs)
IL (1) IL108713A (cs)
NZ (1) NZ262634A (cs)
PT (1) PT686045E (cs)
RU (1) RU2143889C1 (cs)
WO (1) WO1994019020A1 (cs)
ZA (1) ZA941239B (cs)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JPH10508744A (ja) 1994-09-22 1998-09-02 クオドラント ホールディングス ケンブリッジ リミテッド 運動競技の間の水分補給および栄養摂取の用途のための組成物ならびにその製造法
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
RU2161502C2 (ru) * 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
CA2241322C (en) 1996-03-28 2009-01-13 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
RU2203085C2 (ru) * 1996-07-03 2003-04-27 Элзэ Копэрейшн Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU748756B2 (en) * 1997-07-18 2002-06-13 Infimed Therapeutics, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1071465A1 (en) * 1998-03-18 2001-01-31 Ronai, Peter Amorphous glasses for stabilising sensitive products
ES2288018T3 (es) * 1998-04-03 2007-12-16 Novartis Vaccines And Diagnostics, Inc. Formulaciones inyectables de igf que contienen succinato como tampon.
EP1071445A2 (en) * 1998-04-17 2001-01-31 Angiogenix, Incorporated Therapeutic angiogenic factors and methods for their use
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6566329B1 (en) * 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001058428A1 (en) * 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
CA2406790C (en) 2000-04-19 2009-07-07 Genentech, Inc. Sustained release formulations
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
ATE450253T1 (de) * 2000-10-13 2009-12-15 Cambridge Biostability Ltd Pharmazeutische flüssige suspensionen
CA2430318C (en) * 2000-11-29 2009-10-27 Itoham Foods Inc. Powder formulation and method for producing the same
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
EP1372729B1 (en) * 2001-02-23 2009-04-08 Genentech, Inc. Erodible polymers for injection
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US7615234B2 (en) * 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
GB2404865B (en) * 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
DK1458360T3 (da) 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider
JP2005522692A (ja) * 2002-04-05 2005-07-28 パワーザイム，インコーポレイテッド 分析物センサー
US20050175693A1 (en) * 2002-05-09 2005-08-11 Peptron Co., Ltd Substained release formulation of protein and preparation method thereof
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
CN100444848C (zh) * 2002-09-27 2008-12-24 特里梅里斯公司 HIV gp41-衍生肽的改善用药的药物组合物
AU2003277446A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
AU2003303646B2 (en) * 2002-12-31 2010-03-04 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
US20040197413A1 (en) * 2003-04-04 2004-10-07 Genteric, Inc. Spray dry coacervation systems and methods
DE10320609A1 (de) * 2003-05-08 2004-12-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sprühgefriergranulate mit verbesserter Homogenität der Eigenschaftsverteilung und Verfahren zu deren Herstellung
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
US20050095320A1 (en) * 2003-10-29 2005-05-05 Richard Botteri [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) * 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
PT1734971E (pt) * 2004-04-15 2012-02-02 Amylin Pharmaceuticals Inc Dispositivo de libertação sustentada baseado em polímero
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US7133638B2 (en) * 2004-11-18 2006-11-07 Xerox Corporation Scanning method and an image-processing device including the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB2422784A (en) * 2005-02-07 2006-08-09 Caretek Medical Ltd Disposable assembly comprising a needle or stylet
JP5670004B2 (ja) * 2005-03-08 2015-02-18 ファイザー・プロダクツ・インク 抗ｃｔｌａ−４抗体組成物
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
CN100337684C (zh) * 2005-05-11 2007-09-19 北京双鹭药业股份有限公司 一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100342909C (zh) * 2005-05-11 2007-10-17 北京双鹭药业股份有限公司 一种胸腺素α1的水溶液制剂、其制备方法及应用
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
US9309316B2 (en) * 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
PT1989220E (pt) 2006-02-02 2012-03-23 Trimeris Inc Péptidos inibidores de fusão de hiv com propriedades biológicas melhoradas
WO2007104322A1 (en) * 2006-03-13 2007-09-20 Naturin Gmbh & Co Collagen powder and collagen-based thermoplastic composition por preparing conformed articles
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
WO2008118133A2 (en) 2006-09-26 2008-10-02 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
WO2008097497A2 (en) * 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2979729A3 (en) 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CN101677944A (zh) * 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
MX2010003179A (es) * 2007-09-25 2010-04-30 Trimeris Inc Metodos de sintesis para peptidos anti-vih terapeuticos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP5599778B2 (ja) * 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
UA106606C2 (uk) * 2009-03-16 2014-09-25 Родія Оперейшнс Стабілізована біоцидна композиція
US20120070427A1 (en) 2009-06-01 2012-03-22 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
RU2431496C2 (ru) * 2009-09-15 2011-10-20 Общество С Ограниченной Ответственностью "Герофарм" Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
DK2542257T3 (en) 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
WO2011109691A2 (en) 2010-03-05 2011-09-09 Trustees Of Tufts College Silk-based ionomeric compositions
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
US9901648B2 (en) 2012-01-27 2018-02-27 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
WO2014035798A1 (en) 2012-08-30 2014-03-06 Sanofi Silk lyogels for sustained release of protein therapeutics and methods of making and uses
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
KR102291913B1 (ko) * 2014-04-28 2021-08-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆ의 동결건조 제제
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
WO2017104759A1 (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
WO2017159722A1 (ja) 2016-03-17 2017-09-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 活性型肝細胞増殖因子（ｈｇｆ）の製造方法
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2017300392B2 (en) * 2016-07-18 2022-06-16 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JP6404405B1 (ja) * 2017-06-14 2018-10-10 株式会社 資生堂 タブレット型凍結乾燥化粧料
TWI787186B (zh) * 2017-06-19 2022-12-21 日商資生堂股份有限公司 錠型凍結乾燥化妝料
WO2018235147A1 (ja) * 2017-06-19 2018-12-27 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN108169499A (zh) * 2017-11-30 2018-06-15 成都斯马特科技有限公司 一种基于生化试剂盘进行凝血分析的方法
IL281393B2 (en) * 2018-09-14 2025-02-01 Cara Therapeutics Inc Oral formulations of kappa opioid receptor agonists
CA3127191A1 (en) 2019-01-21 2020-07-30 Eclipse Medcorp, Llc Methods, systems and apparatus for separating components of a biological sample
KR20220091580A (ko) 2019-10-31 2022-06-30 이클립스 메드코프 엘엘씨 샘플의 구성요소들을 분리하기 위한 시스템, 방법 및 장치
AU2023215312A1 (en) * 2022-02-01 2024-07-25 Ocular Therapeutix, Inc. A controlled release implant for biologics and corresponding methods of treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
IT1103817B (it) * 1978-06-27 1985-10-14 Guaber Spa Composizione deodorante granulare per posacenere
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
EP0229810B1 (en) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US5312745A (en) * 1987-06-18 1994-05-17 Chromogenix Ab Determination of components active in proteolysis
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
SU1599019A1 (ru) * 1988-02-08 1990-10-15 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получени лиофилизата
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
AT392079B (de) * 1988-03-11 1991-01-25 Voest Alpine Ind Anlagen Verfahren zum druckvergasen von kohle fuer den betrieb eines kraftwerkes
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5312705A (en) * 1990-07-27 1994-05-17 Matsushita Electric Industrial Co., Ltd. Photosensitive materials for electrophotography having a double-layer structure of a charge generation layer and a charge transport layer
WO1992014449A1 (en) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
ATE224184T1 (de) * 1993-10-22 2002-10-15 Genentech Inc Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE175110T1 (de) * 1993-10-22 1999-01-15 Genentech Inc Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
DE69431358T2 (de) * 1993-10-22 2003-06-05 Genentech Inc., San Francisco Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

Also Published As

Publication number Publication date
CZ212795A3 (en) 1996-02-14
ATE197550T1 (de) 2000-12-15
DE69426292D1 (de) 2000-12-21
US5753219A (en) 1998-05-19
US5804557A (en) 1998-09-08
WO1994019020A1 (en) 1994-09-01
NZ262634A (en) 1997-02-24
IL108713A (en) 1999-12-22
ES2153418T3 (es) 2001-03-01
CN1118143A (zh) 1996-03-06
AU6241294A (en) 1994-09-14
US5589167A (en) 1996-12-31
PT686045E (pt) 2001-04-30
JP3698721B2 (ja) 2005-09-21
EP0686045A1 (en) 1995-12-13
GR3035383T3 (en) 2001-05-31
JPH08507064A (ja) 1996-07-30
IL108713A0 (en) 1994-05-30
RU2143889C1 (ru) 2000-01-10
EP0686045B1 (en) 2000-11-15
DE69426292T2 (de) 2001-05-17
AU685784B2 (en) 1998-01-29
CZ296649B6 (cs) 2006-05-17
CN1108823C (zh) 2003-05-21
ZA941239B (en) 1995-08-23

Similar Documents

Publication Publication Date Title
DK0686045T3 (da) Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
TW263423B (cs)
IT1270882B (it) Oligopeptidi ad attivita' fungicida
DK1351703T3 (da) Anvendelse af et polypeptid omfattende det ekstracellulære domæne af IL-20RA og IL-20RB til behandling af inflammation
FI954601L (fi) Rekombinanttisia alfavirusvektoreita
DK0580635T3 (da) Modificerede plantevirus som vektorer
ATE204571T1 (de) O-hydroxyphenyl-s-triazine enthaltende stabilisierte polymere
NO942363L (no) Hypoglycemiske midler
FI912348A0 (fi) Stabiliserad fgf sammansaettning.
FI913833L (fi) Ringsubstituerade 2-amino -1,2,3,4-tetrahydronaftalener, 3-aminokromaner och 3-aminotiokromaner.
DK0552240T3 (da) Ny metode til behandling af depression
DE69131667D1 (de) Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität
DK1027348T3 (da) 2-(2'-hydroxyphenyl)benzotriazoler anvendt som UV-stabilisatorer
DE59101819D1 (de) Stabilisierung von organischen Polyisocyanaten.
NO910522D0 (no) Fremgangsmaate for forhindring av "blomstring" paa mineralske substrater, samt betongstein som er beskyttet ved hjelpav fremgangsmaaten.
IT1237993B (it) Procedimento per la stabilizzazione particolarmente di mosto d'uva.
NO912293D0 (no) Magnetometer basert paa optisk pumping med bruk av kontrollert polarisasjon.
FI915125L (fi) Synergistiska kombinationer av idopropargylfoereningar med hexahydro-1,3,5-tris (2-hydroxietyl)-s -triazin foer kontroll av svamp- och bakterietillvaext i metallbearbetningsvaetskor.
FI955829A0 (fi) Heterosyklinen kemia
FR2689120B1 (fr) Procédé de stabilisation de mâchefer.
NO910357D0 (no) Innretning til feilmoensterregenerering ved "soft"-desisjonsdekoding av blokkoder.
ATE154054T1 (de) Stabilisiertes 1,1-dichloro-1-fluoroäthan
ITMI911604A1 (it) Procedimento per la preparazione della n- (2, 6-diclorofenil) -n-fenil-n-(cloroacetil)-ammina.
DK0431331T3 (da) Varmehærdbare stofblandinger
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav